CDK4 and neoplasm: In a recent study, a CRISPR-CAS9 loss of function screen revealed a spectrum of functional genes whose inhibition might complement the tumor inhibition properties of CDK4/6 inhibitors in PDAC, in which HDAC genes were identified as positive hits [49].